BC Innovations | Aug 16, 2018
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse and rat studies suggest inhibiting PANX1 or its activator P2RX7 in spinal microglia, or an antibody-drug conjugate (ADC) targeting the microglia, could help treat joint pain. In spinal cord samples from a...
BC Innovations | Feb 13, 2018
Distillery Therapeutics

Inflammation; infectious disease

INDICATION: Inflammatory disease; sepsis In vitro and mouse studies suggest inhibiting the MAC-1-CD40L interaction could help treat systemic inflammatory response syndrome (SIRS) and sepsis. In a mouse cell-based assay, a mAb against the M7 motif...
BC Innovations | Jun 7, 2017
Distillery Therapeutics

Cardiovascular

INDICATION: Thrombosis Mouse studies suggest inhibiting the MAC-1 - GP1BA interaction could help treat thrombosis. In a mouse model of microvascular thrombosis, knockout of MAC-1 decreased platelet accumulation in arterioles compared with normal MAC-1 expression. In...
BioCentury | May 12, 2017
Strategy

Vertical vision

Shire plc ’s deal with Parion Sciences Inc. is a step toward building vertically in ophthalmics, much like it has done in hereditary angioedema and hemophilia. On May 1, Shire gained exclusive, worldwide rights to...
BC Extra | May 1, 2017
Company News

Shire, Parion in deal for ENaC inhibitor for dry eye

Parion Sciences Inc. (Durham, N.C.) granted Shire plc (LSE:SHP; NASDAQ:SHPG) exclusive, worldwide rights to P-321 ophthalmic solution , an epithelial sodium channel (ENaC) inhibitor in development to treat dry eye disease. Parion received $20 million up...
BC Innovations | Mar 8, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Zebrafish studies suggest inhibiting TGFβ1 or LFA-1 could help treat metastatic breast cancer. In patient samples, levels of TGFβ1 were higher in primary tumors than in surrounding normal tissue. In two xenograft...
BC Innovations | Jan 25, 2017
Distillery Therapeutics

Renal

INDICATION: Renal Monkey studies suggest inhibiting MAC-1 could help treat chronic kidney disease (CKD) associated with acute kidney injury (AKI). In a monkey model of AKI-induced CKD, a mAb inhibiting the CR3 portion of MAC-1...
BC Week In Review | Sep 5, 2016
Company News

Shire sales and marketing update

Shire launched Xiidra lifitegrast in the U.S. to treat signs and symptoms of dry eye disease in adults. The wholesale acquisition cost (WAC) of a 60-drop container is $426.73. Patients receive one drop of the...
BC Week In Review | Jul 18, 2016
Clinical News

Xiidra lifitegrast regulatory update

FDA approved an NDA from Shire for Xiidra lifitegrast to treat signs and symptoms of dry eye disease in adults. Shire plans to launch the product this quarter. Xiidra is an eye drop formulation of...
BC Extra | Jul 12, 2016
Company News

FDA approves Shire's Xiidra

Shire plc (LSE:SHP; NASDAQ:SHPG) said FDA approved Xiidra lifitegrast ( SHP606 ) to treat signs and symptoms of dry eye disease in adults. The company expects to launch Xiidra this quarter. Shire obtained Xiidra via its 2013...
Items per page:
1 - 10 of 62